{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:26:52Z","timestamp":1763036812465},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087794","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T22:58:51Z","timestamp":1391209131000},"page":"e87794","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-\u03b1 Monotherapy"],"prefix":"10.1371","volume":"9","author":[{"given":"Mette","family":"Ilander","sequence":"first","affiliation":[]},{"given":"Anna","family":"Kreutzman","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Rohon","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Melo","sequence":"additional","affiliation":[]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[]},{"given":"Jukka","family":"Vakkila","sequence":"additional","affiliation":[]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"R Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"MW Deininger","year":"2000","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138945011794815301","article-title":"Interferon alpha for treatment of chronic myeloid leukemia","volume":"12","author":"B Simonsson","year":"2011","journal-title":"Current Drug Targets"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","article-title":"Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients","volume":"114","author":"M Talpaz","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","article-title":"Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy","volume":"79","author":"MS Lee","year":"1992","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2002.20.1.214","article-title":"Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa","volume":"20","author":"FX Mahon","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"F Bonifazi","year":"2001","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","article-title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukemia","volume":"97","author":"M Deng","year":"2001","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.leu.2400965","article-title":"Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia","volume":"12","author":"J Cortes","year":"1998","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.leu.2400919","article-title":"Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon","volume":"12","author":"T Oka","year":"1998","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"A Burchert","year":"2003","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"B Simonsson","year":"2011","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"SG O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"ref17","first-page":"311","article-title":"[A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-alpha]","volume":"33","author":"SH Wu","year":"2012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Koskenvesa P KA, Rohon P, Pihlman M, Vakkila E <etal>et al<\/etal>.. (2013) Imatinib and pegylated IFN-alpha2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. In press.","DOI":"10.1111\/ejh.12258"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"A Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","article-title":"Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile","volume":"6","author":"A Kreutzman","year":"2011","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"C Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"N Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref24","first-page":"1","article-title":"Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy","volume":"0","author":"M Ilander","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-012-1005-1","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95","author":"H Itonaga","year":"2012","journal-title":"Int J Hematol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","article-title":"Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy","volume":"105","author":"DJ Powell Jr","year":"2005","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"C Yee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.4049\/jimmunol.172.6.3437","article-title":"Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly","volume":"172","author":"Y Deng","year":"2004","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/j.leukres.2009.03.024","article-title":"CD8+ memory T cells predominate over naive T cells in therapy-free CML patients with sustained major molecular response","volume":"33","author":"K Usuki","year":"2009","journal-title":"Leuk Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-4933-7-4","article-title":"The effect of ageing on human lymphocyte subsets: comparison of males and females","volume":"7","author":"J Yan","year":"2010","journal-title":"Immun Ageing"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1084\/jem.155.3.768","article-title":"Helper activity is required for the in vivo generation of cytotoxic T lymphocytes","volume":"155","author":"JA Keene","year":"1982","journal-title":"J Exp Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11824","article-title":"T-helper-1-cell cytokines drive cancer into senescence","volume":"494","author":"H Braumuller","year":"2013","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1084\/jem.186.1.65","article-title":"Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help","volume":"186","author":"SR Bennett","year":"1997","journal-title":"J Exp Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/10428199509059647","article-title":"Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha","volume":"18","author":"G Pawelec","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","article-title":"Immunological effects of interferon-alpha on chronic myelogenous leukemia","volume":"44","author":"FA de Castro","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cyto.2013.09.016","article-title":"Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations","volume":"65","author":"H Sun","year":"2014","journal-title":"Cytokine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-11-253286","article-title":"CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells","volume":"116","author":"K Juelke","year":"2010","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1084\/jem.20100479","article-title":"Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection","volume":"208","author":"JC Sun","year":"2011","journal-title":"J Exp Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature07665","article-title":"Adaptive immune features of natural killer cells","volume":"457","author":"JC Sun","year":"2009","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"B Foley","year":"2012","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"14725","DOI":"10.1073\/pnas.1110900108","article-title":"Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection","volume":"108","author":"S Lopez-Verges","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: an update and future directions","volume":"132","author":"KS Campbell","year":"2013","journal-title":"J Allergy Clin Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T23:23:29Z","timestamp":1597447409000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087794"}},"subtitle":[],"editor":[{"given":"Matthaios","family":"Speletas","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087794","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}